Top

Journal of Occupational Medicine and Toxicology

Published in:

Open Access 01-12-2021 | Chronic Obstructive Lung Disease | Study protocol

Respiratory Disease Occupational Biomonitoring Collaborative Project (ROBoCoP): A longitudinal pilot study and implementation research in the Parisian transport company

Authors: I. Guseva Canu, M. Hemmendinger, J. J. Sauvain, G. Suarez, N. B. Hopf, J. A. Pralong, T. Ben Rayana, S. Besançon, K. Sakthithasan, V. Jouannique, A. Debatisse

Published in: Journal of Occupational Medicine and Toxicology | Issue 1/2021

Abstract

The ROBoCoP project is launched within the EU COST Action CA16113 “CliniMARK” aiming to increase the number of clinically validated biomarkers and focused on chronic obstructive pulmonary disease (COPD) biomarker development and validation. ROBoCoP encompasses two consecutive studies consisting of a pilot study followed by a field study. The pilot study is a longitudinal exposure assessment and biomarker study aiming at: 1-understanding the suitability of the candidate biomarkers in surveying populations at risk such as workers exposed to COPD causing agents; 2-determining the best sampling plan with respect to the half-life of the candidate biomarkers; 3-implementing and validating the sampling procedures and analytical methods; 4-selecting the best suitable biomarkers to be measured in the field. Each study participant is surveyed every day during the 6–8 h work-shifts for two consecutive weeks. The field study has an implementation research designe that enabled us to demonstrate the applicability of the standardized protocol for biomarker measurements in occupational settings while also assessing the biomarkers’ validity. ROBoCoP will focus on particulate matter (PM) exposure measurements, exposure biomarkers and a series of effect biomarkers, including markers of lipoperoxidation: 8-isoprostane, malondialdehyd in exhaled breath condensate (EBC) and urine, potential markers of nitrosative stress: NO₂⁻, NO₃⁻ and formate anion in EBC; markers of DNA oxidation: 8-hydroxy-2’deoxyguanosine in EBC and urine, marker of genotoxicity: micronuclei in buccal cells, and oxidative potential in exhaled air (OPEA). OPEA appears particularly promising as a clinical biomarker for detecting COPD, and will be tested independently and as part of a biomarker panel. COPD diagnosis will be performed by an experienced occupational physician according to international diagnostic standards and confirmed by a pulmonologist.

This research will include approximatively 300 underground subway workers randomly selected from the personnel registry of a large Parisian transport company. Underground subways are suggested as the most PM polluted urban transport environment. We believe this occupational exposure is relevant for biomonitoring of workers and early detection of respiratory diseases.

CA16113 CA. CliniMARK: ‘good biomarker practice’ to increase the number of clinically validated biomarkers. 2017. Available from: http://www.cost.eu/COST_Actions/ca/CA16113.

WHO. The top 10 causes of death: WHO; 2017 [Fact Sheet]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.

Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608. https://doi.org/10.1001/jama.2013.13805.CrossRefPubMed

Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. https://doi.org/10.7189/jogh.05.020415.CrossRefPubMedPubMedCentral

Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693–718. https://doi.org/10.1164/rccm.200811-1757ST.CrossRefPubMed

Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet (London, England). 2015;385(9971):899–909.CrossRef

Caillaud D, Lemoigne F, Carre P, Escamilla R, Chanez P, Burgel PR, et al. Association between occupational exposure and the clinical characteristics of COPD. BMC Public Health. 2012;12(1):302. https://doi.org/10.1186/1471-2458-12-302.CrossRefPubMedPubMedCentral

Kraim-Leleu M, Lesage FX, Drame M, Lebargy F, Deschamps F. Occupational risk factors for COPD: a case-control study. PLoS One. 2016;11(8):e0158719. https://doi.org/10.1371/journal.pone.0158719.CrossRefPubMedPubMedCentral

Ling SH, van Eeden SF. Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2009;4:233–43. https://doi.org/10.2147/copd.s5098.CrossRefPubMedPubMedCentral

10.

Rodriguez E, Ferrer J, Marti S, Zock JP, Plana E, Morell F. Impact of occupational exposure on severity of COPD. Chest. 2008;134(6):1237–43. https://doi.org/10.1378/chest.08-0622.CrossRefPubMed

11.

Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet (London, England). 2009;374(9691):733–43.CrossRef

12.

van Eeden SF. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):61–7. https://doi.org/10.1513/pats.200406-035MS.CrossRefPubMed

13.

Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet. 2015;385(9979):1778–88. https://doi.org/10.1016/S0140-6736(15)60647-X.CrossRefPubMedPubMedCentral

14.

Smith JD, Barratt BM, Fuller GW, Kelly FJ, Loxham M, Nicolosi E, et al. PM2.5 on the London underground. Environ Int. 2020;134:105188.CrossRef

15.

Loxham M, Cooper MJ, Gerlofs-Nijland ME, Cassee FR, Davies DE, Palmer MR, et al. Physicochemical characterization of airborne particulate matter at a mainline underground Railway Station. Environ Sci Technol. 2013;47(8):3614–22. https://doi.org/10.1021/es304481m.CrossRefPubMedPubMedCentral

16.

Seaton A, Cherrie J, Dennekamp M, Donaldson K, Hurley JF, Tran CL. The London underground: dust and hazards to health. Occup Environ Med. 2005;62(6):355–62. https://doi.org/10.1136/oem.2004.014332.CrossRefPubMedPubMedCentral

17.

Park D, Oh M, Yoon Y, Park E, Lee K. Source identification of PM10 pollution in subway passenger cabins using positive matrix factorization. Atmos Environ. 2012;49:180–5. https://doi.org/10.1016/j.atmosenv.2011.11.064.CrossRef

18.

Bergamaschi E, Guseva Canu I, Prina-Mello A, Magrini A. Biomonitoring. Adverse effects of engineered nanomaterials. Amsterdam: Elsevier; 2017. p. 125–58.CrossRef

19.

Bergamaschi E, Poland C, Guseva Canu I, Prina-Mello A. The role of biological monitoring in nano-safety. Nano Today. 2015;10(3):274–7. https://doi.org/10.1016/j.nantod.2015.02.001.CrossRef

20.

Fischer B, Voynow J, Ghio A. COPD: balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 2015;10:261–76.CrossRef

21.

Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013;144(1):266–73. https://doi.org/10.1378/chest.12-2664.CrossRefPubMed

22.

Zinellu E, Zinellu A, Fois AG, Carru C, Pirina P. Circulating biomarkers of oxidative stress in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2016;17(1):150.CrossRef

23.

Riediker M, Zink D, Kreyling W, Oberdörster G, Elder A, Graham U, et al. Particle toxicology and health - where are we? Particle Fibre Toxicol. 2019;16(1):19. https://doi.org/10.1186/s12989-019-0302-8.CrossRef

24.

Kim HJ, Choi MG, Park MK, Seo YR. Predictive and prognostic biomarkers of respiratory diseases due to particulate matter exposure. J Cancer Prev. 2017;22(1):6–15. https://doi.org/10.15430/JCP.2017.22.1.6.CrossRefPubMedPubMedCentral

25.

Paone G, Leone A, Batzella S, Conti V, Belli F, De Marchis L, et al. Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers. Inflamm Res. 2012;62(3):325–32. https://doi.org/10.1007/s00011-012-0585-9.CrossRefPubMed

26.

Wendt CH, Nelsestuen G, Harvey S, Gulcev M, Stone M, Reilly C. Peptides in Bronchoalveolar lavage in chronic obstructive pulmonary disease. PLoS One. 2016;11(5):e0155724. https://doi.org/10.1371/journal.pone.0155724.CrossRefPubMedPubMedCentral

27.

Mirowsky J, Gordon T. Noninvasive effects measurements for air pollution human studies: methods, analysis, and implications. J Expo Sci Environ Epidemiol. 2015;25(4):354–80. https://doi.org/10.1038/jes.2014.93.CrossRefPubMedPubMedCentral

28.

Rinaldo M, Andujar P, Lacourt A, Martinon L, Canal Raffin M, Dumortier P, et al. Perspectives in biological monitoring of inhaled Nanosized particles. Ann Occup Hyg. 2015;59(6):669–80. https://doi.org/10.1093/annhyg/mev015.CrossRefPubMed

29.

Laulagnet A, Sauvain JJ, Concha-Lozano N, Riediker M, Suárez G. Sensitive photonic system to measure oxidative potential of airborne nanoparticles and ROS levels in exhaled air. Procedia Eng. 2015;120:632–6. https://doi.org/10.1016/j.proeng.2015.08.659.CrossRef

30.

Suarez G. OxAirDirect −115-151 Rapport Final Dispositif de détection portatif pour la mesure directe de marqueurs du stress oxydant (ROS) dans l’air expiré. Lausanne: IST; 2017.

31.

Andreoli R, Manini P, Corradi M, Mutti A, Niessen WM. Determination of patterns of biologically relevant aldehydes in exhaled breath condensate of healthy subjects by liquid chromatography/atmospheric chemical ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17(7):637–45. https://doi.org/10.1002/rcm.960.CrossRefPubMedPubMedCentral

32.

Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J. 2008;32(2):472–86. https://doi.org/10.1183/09031936.00116107.CrossRefPubMed

33.

Hillas G, Loukides S, Kostikas K, Bakakos P. Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect? Curr Med Chem. 2009;16(22):2824–38. https://doi.org/10.2174/092986709788803178.CrossRefPubMed

34.

Greenwald R, Fitzpatrick AM, Gaston B, Marozkina NV, Erzurum S, Teague WG. Breath Formate is a marker of airway S-Nitrosothiol depletion in severe asthma. PLoS One. 2010;5(7):e11919. https://doi.org/10.1371/journal.pone.0011919.CrossRefPubMedPubMedCentral

35.

Greenwald R, Johnson BA, Hoskins A, Dworski R. Exhaled breath condensate formate after inhaled allergen provocation in atopic asthmatics in vivo. J Asthma: Official Journal of the Association for the Care of Asthma. 2013;50(6):619–22. https://doi.org/10.3109/02770903.2013.783065.CrossRef

36.

Strasser G, Hiebaum S, Neuberger M. Commuter exposure to fine and ultrafine particulate matter in Vienna. Wien Klin Wochenschr. 2018;130(1):62–9. https://doi.org/10.1007/s00508-017-1274-z.CrossRefPubMed

37.

Posselt K-P, Neuberger M, Köhler D. Fine and ultrafine particle exposure during commuting by subway in Vienna. Wien Klin Wochenschr. 2019;131(15):374–80. https://doi.org/10.1007/s00508-019-1516-3.CrossRefPubMedPubMedCentral

38.

Ozgen S, Ripamonti G, Malandrini A, Ragettli MS, Lonati G. Particle number and mass exposure concentrations by commuter transport modes in Milan. Italy AIMS Environ Sci. 2016;3(2):168–84. https://doi.org/10.3934/environsci.2016.2.168.CrossRef

39.

Yan C, Zheng M, Yang Q, Zhang Q, Qiu X, Zhang Y, et al. Commuter exposure to particulate matter and particle-bound PAHs in three transportation modes in Beijing. China Environ Pollution. 2015;204:199–206. https://doi.org/10.1016/j.envpol.2015.05.001.CrossRef

40.

Moreno T, Reche C, Rivas I, Cruz Minguillón M, Martins V, Vargas C, et al. Urban air quality comparison for bus, tram, subway and pedestrian commutes in Barcelona. Environ Res. 2015;142:495–510. https://doi.org/10.1016/j.envres.2015.07.022.CrossRefPubMed

41.

Smith PGMR, Ross DA. Field trials of health interventions: a toolbox. 3rd ed. London: Oxford University Press; 2015. p. 444. https://doi.org/10.1093/med/9780198732860.001.0001.CrossRef

42.

GOLD. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2017/

43.

Campagna D, Ihaddadene K, Randon A, Mattei N, Marchand JL, Le Naour C, et al. Analyse de la mortalité des agents et ex-agents de la RATP sur la période 1980–1999 Cohorte EDGAR. Paris: InVS-RATP; 2008.

44.

Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. ERS global lung function initiative. Eur Respir J. 2012;40(6):1324–43. https://doi.org/10.1183/09031936.00080312.CrossRefPubMedPubMedCentral

45.

Sauvain J-J, Setyan A, Wild P, Tacchini P, Lagger G, Storti F, et al. Biomarkers of oxidative stress and its association with the urinary reducing capacity in bus maintenance workers. J Occup Med Toxicol. 2011;6(1):18. https://doi.org/10.1186/1745-6673-6-18.CrossRefPubMedPubMedCentral

46.

Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath condensate as a matrix for combustion-based nanoparticle exposure and health effect evaluation. J Aerosol Med Pulm Drug Deliv. 2014;27(6):449–58. https://doi.org/10.1089/jamp.2013.1101.CrossRefPubMed

47.

Sauvain JJ, Suarez G, Edmé JL, Bezerra OMPA, Silveira KG, Amaral LS, et al. Method validation of nanoparticle tracking analysis to measure pulmonary nanoparticle content: the size distribution in exhaled breath condensate depends on occupational exposure. J Breath Res. 2017;11(1):016010. https://doi.org/10.1088/1752-7163/aa56dd.CrossRefPubMed

48.

Sauvain JJ, Edmé JL, Wild P, Suarez G, Bezerra OMPA, Talvani A, et al. Does exposure to inflammatory particles modify the pattern of anion in exhaled breath condensate? J Breath Res. 2020;14(2):026005. https://doi.org/10.1088/1752-7163/ab5d88.CrossRefPubMed

49.

Graczyk H, Lewinski N, Zhao J, Sauvain JJ, Suarez G, Wild P, et al. Increase in oxidative stress levels following welding fume inhalation: a controlled human exposure study. Part Fibre Toxicol. 2016;13(1):31. https://doi.org/10.1186/s12989-016-0143-7.CrossRefPubMedPubMedCentral

50.

Loxham M, Nieuwenhuijsen MJ. Health effects of particulate matter air pollution in underground railway systems - a critical review of the evidence. Part Fibre Toxicol. 2019;16(1):12. https://doi.org/10.1186/s12989-019-0296-2.CrossRefPubMedPubMedCentral

51.

Wen Y, Leng J, Shen X, Han G, Sun L, Yu F. Environmental and health effects of ventilation in subway stations: A literature review. Int J Environ Res Public Health. 2020;17(3):1084.CrossRef

52.

Unisanté. Swiss Health Study- Pilot phase 2021 (updated 04.01.2021). Available from: https://www.etude-sur-la-sante.ch/letude/.

53.

Graille M, Wild P, Sauvain JJ, Hemmendinger M, Guseva Canu I, Hopf NB. Urinary 8-OHdG as a biomarker for oxidative stress: a systematic literature review and meta-analysis. Int J Mol Sci. 2020;21(11):3743.CrossRef

54.

Graille M, Wild P, Sauvain JJ, Hemmendinger M, Guseva Canu I, Hopf NB. Urinary 8-isoprostane as a biomarker for oxidative stress. A systematic review and meta-analysis. Toxicol Lett. 2020;328:19–27. https://doi.org/10.1016/j.toxlet.2020.04.006.CrossRefPubMed

55.

Hemmendinger M, Wild P, Shoman Y, Graille M, Bergamaschi E, Hopf N, et al. Reference ranges of oxidative stress biomarkers selected for non-invasive biological surveillance of nanotechnology workers: study protocol and meta-analysis results for 8-OHdG in exhaled breath condensate. Toxicol Lett. 2020;327:41–7. https://doi.org/10.1016/j.toxlet.2020.03.021.CrossRefPubMed

56.

Hopf NB, Bolognesi C, Danuser B, Wild P. Biological monitoring of workers exposed to carcinogens using the buccal micronucleus approach: a systematic review and meta-analysis. Mutat Res. 2019;781:11–29. https://doi.org/10.1016/j.mrrev.2019.02.006.CrossRefPubMed

57.

Hopf NB, Danuser B, Bolognesi C, Wild P. Age related micronuclei frequency ranges in buccal and nasal cells in a healthy population. Environ Res. 2020;180:108824. https://doi.org/10.1016/j.envres.2019.108824.CrossRefPubMed

58.

Shoman Y, Wild P, Hemmendinger M, Graille M, Sauvain JJ, Hopf NB, et al. Reference ranges of 8-isoprostane concentrations in Exhaled Breath Condensate (EBC): a systematic review and meta-analysis. Int J Mol Sci. 2020;21(11):3822.CrossRef

Title: Respiratory Disease Occupational Biomonitoring Collaborative Project (ROBoCoP): A longitudinal pilot study and implementation research in the Parisian transport company
Authors: I. Guseva Canu
M. Hemmendinger
J. J. Sauvain
G. Suarez
N. B. Hopf
J. A. Pralong
T. Ben Rayana
S. Besançon
K. Sakthithasan
V. Jouannique
A. Debatisse
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Chronic Obstructive Lung Disease
Biomarkers
Published in: Journal of Occupational Medicine and Toxicology / Issue 1/2021
Electronic ISSN: 1745-6673
DOI: https://doi.org/10.1186/s12995-021-00312-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Respiratory Disease Occupational Biomonitoring Collaborative Project (ROBoCoP): A longitudinal pilot study and implementation research in the Parisian transport company

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

How to evaluate digital leadership: a cross-sectional study

Pushing occupational rehabilitation – implementation of a therapy diary in the outpatient aftercare of psychosomatic rehabilitation may promote the occupational reintegration process: a survey of therapists and patients

Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception

Mortality from Parkinson’s disease and other causes among a workforce manufacturing paraquat: an updated retrospective cohort study

Reflection on leadership behavior: potentials and limits in the implementation of stress-preventive leadership of middle management in hospitals – a qualitative evaluation of a participatory developed intervention

Ongoing downplaying of the carcinogenicity of chrysotile asbestos by vested interests